Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNIK | Q9UKE5 | 2/20 | 0.39 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10258926 | 0.90 | CRHR1 (0.40) | TNIKCAPN1KAT6ACRHR1MGLL | |
| SCHEMBL519254 | 0.86 | PDE10A (0.47) | CAPN1KAT6APDE10ACRHR1FGFR1 | |
| SCHEMBL10258903 | 0.85 | PDE10A (0.38) | TNIKCAPN1KAT6APDE10ACRHR1 | |
| SCHEMBL16625711 | 0.81 | L3MBTL1 (0.41) | METL3MBTL1 | |
| SCHEMBL10258263 | 0.79 | L3MBTL1 (0.39) | METL3MBTL1 | |
| SCHEMBL10266950 | 0.79 | ADORA3 (0.45) | PDE10AMETMGLL | |
| SCHEMBL17389338 | 0.78 | PDE10A (0.49) | KAT6APDE10AFGFR1 | |
| SCHEMBL15973835 | 0.77 | PDE10A (0.47) | KAT6APDE10AL3MBTL1F10CYP3A4 | |
| SCHEMBL14973927 | 0.77 | L3MBTL1 (0.38) | TNIKCAPN1KAT6APDE10AFGFR1 | |
| SCHEMBL519089 | 0.76 | CRHR1 (0.41) | CAPN1PDE10ACRHR1TP53HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-04-27 | — | — | US | disclosed |
| US-9550756-B2 | Pyridazinone compounds as phosphodiesterase inhibitors and methods of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-01-24 | — | — | US | disclosed |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL (JP) | 2015-04-09 | — | — | US | disclosed |
| US-8778944-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-15 | — | — | US | disclosed |
| US-8513251-B2 | Pyridazinone compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8354411-B2 | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | TANIGUCHI TAKAHIKO (GB) | 2012-11-01 | — | — | US | disclosed |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277431-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | TNIK 2838/4885CAPN1 4097/4885KAT6A 1311/4885 |
| US-20120277430-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | TNIK 2838/4885CAPN1 4097/4885KAT6A 1311/4885 |
| US-20150099757-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | TNIK 2641/4885CAPN1 3922/4885KAT6A 1158/4885 |
| US-20170114044-A1 | PYRIDAZINONE COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS AND METHODS OF TREATING DISORDERS | PDE3A, PDE5A, PDE3B | TNIK 2748/4885CAPN1 3963/4885KAT6A 1213/4885 |
| US-20120277204-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | TNIK 2838/4885CAPN1 4097/4885KAT6A 1311/4885 |
| US-20120028951-A1 | PYRIDAZINONE COMPOUNDS | PDE3A, PDE5A, PDE3B | TNIK 2838/4885CAPN1 4097/4885KAT6A 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.